Chase Investment Counsel Corp Acquires New Stake in DaVita Inc. (NYSE:DVA)

Chase Investment Counsel Corp acquired a new stake in DaVita Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 21,172 shares of the company’s stock, valued at approximately $2,933,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Franklin Resources Inc. grew its position in shares of DaVita by 42.0% in the fourth quarter. Franklin Resources Inc. now owns 7,866 shares of the company’s stock valued at $824,000 after purchasing an additional 2,325 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of DaVita in the 4th quarter worth $385,000. Treasurer of the State of North Carolina raised its holdings in shares of DaVita by 1.0% during the 4th quarter. Treasurer of the State of North Carolina now owns 24,737 shares of the company’s stock worth $2,591,000 after acquiring an additional 234 shares during the period. TFO Wealth Partners LLC boosted its position in shares of DaVita by 56,133.3% during the 4th quarter. TFO Wealth Partners LLC now owns 1,687 shares of the company’s stock valued at $177,000 after acquiring an additional 1,684 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of DaVita by 4.2% in the fourth quarter. California State Teachers Retirement System now owns 87,217 shares of the company’s stock valued at $9,137,000 after purchasing an additional 3,543 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DVA. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. TD Cowen increased their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Truist Financial lifted their target price on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, DaVita presently has an average rating of “Hold” and an average price target of $157.00.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock worth $27,387,069 in the last ninety days. 2.00% of the stock is owned by corporate insiders.

DaVita Trading Up 0.5 %

Shares of NYSE DVA opened at $163.08 on Monday. The stock has a fifty day simple moving average of $150.14 and a 200-day simple moving average of $142.14. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $166.04. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The stock has a market capitalization of $14.30 billion, a PE ratio of 18.53, a PEG ratio of 0.93 and a beta of 0.87.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same period in the prior year, the firm earned $2.08 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.